• TriSalus Life Sciences’ third-quarter 2026 net loss attributable to common stockholders narrowed 78% year over year to $8.9 million.
• Revenue rose 11% year over year to $12.9 million, driven primarily by higher TriNav unit sales.
• FDA clearance for TriNav Advance enables pressure-enabled drug delivery to small distal vessels through physicians’ chosen microcatheters.
• Expanded Medicare reimbursement for pressure-enabled drug delivery procedures takes effect January 1, 2027, including national payment in office-based labs.
• Full-year 2026 revenue guidance was revised to $46 million–$48 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trisalus Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-072513), on November 10, 2026, and is solely responsible for the information contained therein.